Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Cellix Ltd. Launches the First Semi-Automated, High Throughput Cell-Adhesion Assay Platform

Abstract:
The VenaFlux(TM) Platform Accurately Mimics a Human Capillary

Cellix Ltd. Launches the First Semi-Automated, High Throughput Cell-Adhesion Assay Platform

DUBLIN, Ireland | Posted on January 30th, 2008

Cellix Ltd., an international provider of microfluidic systems in the emerging field of nano-lifesciences, announced today its worldwide launch of its VenaFlux(TM) Platform. The VenaFlux(TM), the first semi-automated, high throughput microfluidic cell- based assay system, measures cell adhesion to antibody-coated or endothelial- cell cultured microchannels, producing IC50 curves under shear stress conditions mimicking physiological flow. The system thereby offers scientists an important and unique tool for drug discovery. The VenaFlux(TM) is simple to use, reduces costly layers of animal model studies, and delivers specific, accurate, and reproducible results.


Using the VenaFlux(TM), scientists can rapidly obtain quantitative analyses and results for potential drug candidates in therapeutic areas including cardiovascular, respiratory, immunologic, autoimmune and oncologic disease states. Relatively rapid analyses reduces drug development costs by accelerating false lead elimination and increasing productivity in pharmaceutical and biotechnology research and development laboratories.

"Understanding how cells behave in human capillaries is an expanding area in global research and development for discovering new patient therapies," said Vivienne Williams, CEO of Cellix Ltd. "Our VenaFlux(TM) accurately replicates cell behavior in human capillaries, an in vitro modeling system that has previously been difficult to achieve.

Cellix's technology provides researchers with a single platform for executing dynamic studies to analyze the effects of drugs on cell adhesion, proliferation and transmigration under well-defined shear stress protocols that replicate physiological conditions. "To date, pharmaceutical companies including AstraZeneca and Amgen, as well as research institutions such as the US National Institutes of Health have adopted Cellix's technology to characterize drug effects," commented Ms. Williams.

About the VenaFlux Platform

The VenaFlux(TM) Platform consists of Cellix's patented Mirus(TM) Nanopump with VenaFluxAssay(TM) software, Vena8(TM) Biochips and DucoCell(TM) analysis software; Carl Zeiss Axiovert(TM) 40 CFL microscope, motorized stage with Z- focus, microscope cage incubator, automated dispenser arm, digital camera for image acquisition and PC. The VenaFlux(TM) Platform can run 8 microcapillaries in 15 minutes, thereby achieving 32 assays in one hour or approximately 1,000 assays per week. The VenaFlux(TM) Platform provides an important new in vitro alternative to expensive animal models while simultaneously cutting down costs on reagents and manpower.

####

About Cellix Ltd.
Cellix Ltd. is a privately held instrumentation and cell-based assay company developing technologies that accurately mimic cellular behavior in vivo for cell-based screening in drug discovery. The Company is headquartered in Dublin, Ireland, and maintains offices in New York City.

For more information, please click here

Contacts:
Julia Umlauf
Cellix Ltd.
+1-917-623-4456

Copyright © Cellix Ltd.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

New non-invasive method can detect Alzheimer's disease early: MRI probe technology shows brain toxins in living animals for first time December 22nd, 2014

Piezoelectricity in a 2-D semiconductor: Berkeley Lab researchers discovery of piezoelectricty in molybdenum disulfide holds promise for future MEMS December 22nd, 2014

Quantum physics just got less complicated December 22nd, 2014

Enzyme Biosensor Used for Rapid Measurement of Drug December 22nd, 2014

Microfluidics/Nanofluidics

“Line dancing bacteria win the 2014 Dolomite and Lab on a Chip Video Competition” December 16th, 2014

Dolomite launches Mitos Dropix® Droplet Splitting System December 1st, 2014

The mysterious 'action at a distance' between liquid containers November 26th, 2014

“Dolomite’s Resealable Chip Interface offers easy access to microfluidic chip surface” November 10th, 2014

Nanomedicine

New non-invasive method can detect Alzheimer's disease early: MRI probe technology shows brain toxins in living animals for first time December 22nd, 2014

Enzyme Biosensor Used for Rapid Measurement of Drug December 22nd, 2014

Creation of 'Rocker' protein opens way for new smart molecules in medicine, other fields December 18th, 2014

Iranian Researchers Produce Electrical Pieces Usable in Human Body December 18th, 2014

Announcements

New non-invasive method can detect Alzheimer's disease early: MRI probe technology shows brain toxins in living animals for first time December 22nd, 2014

Piezoelectricity in a 2-D semiconductor: Berkeley Lab researchers discovery of piezoelectricty in molybdenum disulfide holds promise for future MEMS December 22nd, 2014

Quantum physics just got less complicated December 22nd, 2014

Enzyme Biosensor Used for Rapid Measurement of Drug December 22nd, 2014

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE